Table 3 Upfront therapy with hazard ratio
From: Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients
PTLD group/sub-group | Upfront therapy | n | % | p-value | Hazard ratios | 95% confidence limits |
|---|---|---|---|---|---|---|
Cumulative | RIS alone | 33 | 23.4 | 0.1454 | 0.589 | 0.289–1.201 |
Rituximab (± RIS) | 35 | 24.8 | 0.0309 | 1.930 | 1.062–3.505 | |
Chemotherapy (± RIS, ± rituximab) | 65 | 46.1 | 0.6196 | 0.865 | 0.487–1.535 | |
Monomorphic PTLD | RIS alone | 12 | 13.19 | 0.7359 | 1.163 | 0.484–2.793 |
Rituximab (± RIS) | 25 | 27.47 | 0.2383 | 1.502 | 0.764–2.953 | |
Chemotherapy (± RIS, ± rituximab) | 54 | 59.34 | 0.1939 | 0.651 | 0.341–1.244 | |
Early lesions and polymorphic PTLD | RIS alone | 19 | 52.78 | 0.1545 | 0.396 | 0.111–1.417 |
Rituximab (± RIS) | 10 | 27.78 | 0.0498 | 3.765 | 1.001–14.161 | |
Chemotherapy (± RIS, ± rituximab) | 7 | 19.44 | 0.9151 | 0.919 | 0.193–4.374 |